Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of MK-1045 ± tocilizumab in relapsed/refractory non-Hodgkin lymphoma
2025-523005-15-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2 trial of CN201 in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE and 3 more. Planned start Jun 2026; status: authorised.
02
Drugs
CN201
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2025-523005-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523005-15-00.